Compugen Ltd. Stock
Your prediction
Compugen Ltd. Stock
Compugen Ltd. dominated the market today, gaining €0.12 (6.740%).
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | 6.740% | 5.660% | 4.044% | 58.403% | 44.681% | 214.711% | - |
| Protalix Biotherapeutics Inc. | -1.060% | -1.064% | -24.390% | -13.969% | 21.569% | -7.601% | -51.309% |
| Chromadex Corp | -2.580% | 5.587% | -10.849% | -30.642% | -31.273% | 182.090% | -52.152% |
| Intellia Therapeutics Inc | -1.310% | 5.566% | -4.128% | 87.975% | 45.785% | -65.546% | -83.289% |
Comments
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) had its price target lowered by analysts at Truist Financial Co. from $5.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
